Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough
However, the most important factor is not cost alone
Melittin can also prevent EGF-induced cell invasion through its inhibition of the PI3K/Akt/mTOR signaling pathway, but this is primarily related to breast cancer cells [2]
However, the significant weight changes usually come later on, typically after the 12-week mark
In laboratory and pre-clinical settings, Melanotan 1 has been investigated across a range of melanocortin biology research areas, including: MC1R binding affinity, Gs/adenylate cyclase activation, and cAMP/PKA signalling pathway studies Eumelanin synthesis, tyrosinase upregulation, and melanocyte pigmentation biology Photoprotection and UV-induced DNA damage prevention models Melanocortin receptor selectivity profiling and SAR studies comparison with -MSH, MT-2, and NDP--MSH Erythropoietic protoporphyria (EPP) and porphyria photoprotection models Skin pigmentation and melanogenesis pathway research MC1R-mediated anti-inflammatory signalling in keratinocyte and immune cell models Comparative melanocortin analogue pharmacology MT-1 vs MT-2 vs Bremelanotide Circadian and seasonal melanogenesis regulation studies Melanocortin system interactions with UV exposure and oxidative stress responses What Do Studies Say About Melanotan 1
